What do systematic reviews say?

Naftopidil vs silodosin (alpha‐blocker)

Naftopidil showed no clear difference in cardiovascular adverse events compared with silodosin (alpha‐blocker) (low certainty).

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 0.98 [0.39, 2.44]
  5 studies · 808 participants
  Low

Silodosin vs naftopidil

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 652 participants
  Low

Silodosin vs naftopidil

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 652 participants
  Low

Silodosin vs naftopidil

Silodosin showed no clear difference in treatment withdrawal due to any reason compared with naftopidil (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.25 [0.81, 1.93]
  4 studies · 659 participants
  Low

Silodosin vs naftopidil

Silodosin showed no clear difference in cardiovascular adverse events compared with naftopidil (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.02 [0.41, 2.56]
  5 studies · 808 participants
  Low

Silodosin vs naftopidil

Silodosin probably leads to higher sexual adverse events compared with naftopidil (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 5.93 [2.16, 16.29]
  4 studies · 405 participants
  Moderate